NewAmsterdam Pharma Co N.V. (NAMS) financials: revenue, earnings and cash flow
Fiscal 2020–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Net income in fiscal 2025 was -$204M, a net margin of -905.7%; the best year in this period was 2020 with -$7M.
Over the twelve months to September 30, 2026, revenue was $26M and net income -$205M.
Free cash flow was -$148M in fiscal 2025 and positive in 1 of the 6 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $26M | $23M | $46M | $14M | $103M | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Operating income | — | -$226M | -$176M | -$183M | -$4M | -$35M | -$7M |
| Net income | -$205M | -$204M | -$242M | -$177M | -$23M | -$42M | -$7M |
| EPS (diluted) | $-1.68 | $-1.70 | $-2.01 | $-1.48 | $-0.19 | $-0.35 | $-0.06 |
| R&D | — | $142M | $151M | $159M | $87M | $29M | — |
| Revenue growth | — | −50.6% | +223.4% | −86.3% | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$150M | -$148M | -$159M | -$141M | $11M | -$30M | -$7M |
| Capital spending | -$395000 | -$246000 | -$672000 | -$24000 | -$221000 | -$24000 | -$15952 |
| Free cash flow | -$151M | -$148M | -$159M | -$141M | $10M | -$30M | -$7M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — |
| Stock-based pay | — | $59M | $34M | $25M | $4M | $1M | — |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash | — | $636M | $834M | $340M | $468M | $60M | $10M |
| Debt | — | $202000 | $448000 | $60000 | $126000 | — | — |
| Equity | — | $683M | $758M | $288M | $430M | -$114M | -$73M |
| Total assets | — | $769M | $865M | $347M | $478M | $68M | — |
| Shares (diluted) | 122M | 120M | 120M | 120M | 120M | 120M | 120M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | -1002.9% | -386.9% | -1298.6% | -3.5% | — | — |
| Net margin | -789.9% | -905.7% | -530.2% | -1255.8% | -22.0% | — | — |
| FCF margin | -581.6% | -657.8% | -349.5% | -1002.4% | 10.2% | — | — |
| ROIC | — | -26.1% | -23.3% | -50.1% | -0.7% | — | — |
| ROE | — | -29.8% | -31.9% | -61.4% | -5.3% | 36.7% | 9.7% |
Frequently asked questions
What is NewAmsterdam Pharma Co’s annual revenue?
$23M in fiscal 2025 and $26M over the twelve months to September 30, 2026.
How much profit does NewAmsterdam Pharma Co make?
Net income was -$204M in fiscal 2025 (net margin -905.7%).
Is NewAmsterdam Pharma Co’s revenue growing?
No: revenue fell 50.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.